Trial Profile
A Multicenter Study with a Randomized, Double-Blind, Comparator-Controlled Induction Dosing Period Followed by a Maintenance Dosing Period to Evaluate the Efficacy and Safety of LY2439821 compared to Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Jun 2016
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary) ; Ustekinumab
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- 11 May 2016 Status changed from recruiting to completed.
- 18 Mar 2016 New trial record